Science Explorer Interactive view Map
Company · Greifswald · Germany

Riemser Pharma (Germany)

Research works
28
▼ 32% vs 2013–17
Citations
494
17.6 per fractional work
Top-10% rate
52.5%
record average 16.5%
Open access
48%
world 28%

Not ranked overall: Riemser Pharma (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 4.98× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 1.56× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 8.29× its world share, 0 worksImmunology and Micro…Computer Science: 1.43× its world share, 0 worksComputer ScienceEarth and Planetary Sciences: 2.36× its world share, 0 worksEarth and Planetary …Environmental Science: 1.11× its world share, 0 worksEnvironmental ScienceMedicine: 1.76× its world share, 1 worksMedicineArts and Humanities: 1.93× its world share, 0 worksArts and Humanitiesworld share
more than its size predictsabout as predictedless

Rings at 0.5×, and 2×. Widest outward: Immunology and Microbiology, 8.3×. Every wedge is a field page.

Which keywords describe research at Riemser Pharma (Germany)?

By fractional works in all years, weighted toward what it does more of than the world: Epidemiology, Pathogenesis, Genetic Characterization, Vaccine, Viral Pathogenesis, Immune Response, African Swine Fever and Foot-and-Mouth Disease.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 25 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 25 words, with their numbers
  1. Epidemiology8▲ 7.3×20 topics
  2. Pathogenesis5▲ 32×10 topics
  3. Genetic Characterization4▲ 252×2 topics
  4. Vaccine3▲ 30×6 topics
  5. Viral Pathogenesis3▲ 137×3 topics
  6. Immune Response2▲ 14×6 topics
  7. African Swine Fever2▲ 242×1 topic
  8. Foot-and-Mouth Disease2▲ 242×1 topic
  9. Climate Change2▲ 2.8×5 topics
  10. Vaccines2▲ 101×2 topics
  11. Bluetongue Virus2▲ 266×1 topic
  12. Culicoides Biting Midges2▲ 266×1 topic
  13. Infection2▲ 20×2 topics
  14. Quality of Life1▲ 3.8×3 topics
  15. Genetic Testing1▲ 26×2 topics
  16. Genomic Sequencing1▲ 28×2 topics
  17. Treatment1▲ 3.3×3 topics
  18. Epidemiological Study1▲ 48×2 topics
  19. Myocarditis1▲ 96×1 topic
  20. Norovirus1▲ 71×1 topic
  21. Rotavirus1▲ 71×1 topic
  22. Viral Infection1▲ 53×1 topic
  23. Coronavirus1▲ 30×2 topics
  24. Medical Ethics1▲ 20×1 topic
  25. Patient Rights1▲ 37×1 topic

Which research topics does Riemser Pharma (Germany) publish most on?

By volume in 2022–2025: Vector-Borne Animal Diseases, Viral Infections and Vectors, Human-Animal Interaction Studies and Rabies epidemiology and control.

  1. 1 Vector-Borne Animal Diseases Ecology, Evolution, Behavior and Systematics 0 works
  2. 2 Viral Infections and Vectors Infectious Diseases 0 works
  3. 3 Human-Animal Interaction Studies Genetics 0 works
  4. 4 Rabies epidemiology and control Virology 0 works
  5. 5 Virology and Viral Diseases Epidemiology 0 works
  6. 6 Animal Disease Management and Epidemiology Agronomy and Crop Science 0 works
  7. 7 Web and Library Services Information Systems 0 works
  8. 8 Mosquito-borne diseases and control Public Health, Environmental and Occupational Health 0 works
  9. 9 Library Collection Development and Digital Resources Information Systems 0 works
  10. 10 Viral gastroenteritis research and epidemiology Infectious Diseases 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available47.7%not open52.3%

World: 28% of research is openly available.

with international co-authors31.0%domestic only69.0%

World: 19% is written across borders.

How has Riemser Pharma (Germany)'s research output changed?

Output in 2018–2022 was 32% lower than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Greifswald

All research institutions in Greifswald

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.